Communiqués Onconetix, Inc.

Actions

ONCO

US68237Q4010

Produits pharmaceutiques

Cours en clôture Nasdaq 10/09/2026			Varia. 5j.	Varia. 1 janv.
0,7822 ^USD	-3,81%		+5,85%	-99,00%

01/09	La Maison Blanche conclut un accord avec neuf laboratoires pour réduire le prix des médicaments	MT
13/08	Onconetix, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

03/09	Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events	AQ
06/08	Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series	AQ
05/08	Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG	AQ
07/07	Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation	AQ
24/06	Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District	AQ
19/05	Onconetix, Inc. Announces 1-for-10 Reverse Stock Split	AQ
13/05	Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study	AQ
09/04	Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson	AQ
02/04	Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update	AQ
31/03	Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors	AQ
26/03	Onconetix Highlights Realbotix's Role in Ericsson's World-First 6G Trial Demonstration	AQ
25/03	Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration	AQ
23/03	Onconetix, Inc. Announces 1-for-5 Reverse Stock Split	AQ
12/02	Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company	AQ
30/12	Oncopeptides AB - Research shows that Pepaxti is effective in high-risk myeloma	AQ
24/11	Oncopeptides announces the Nomination Committee	AQ
12/11	Oncopeptides AB - Annals of Hematology, Expert consensus supports use of Pepaxti in myeloma	AQ
17/10/25	Oncopeptides AB - Journal of Cancer Research and Clinical Oncology, Exceptional long-term responses to Pepaxti	AQ
26/09/25	Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.	AQ
26/09/25	Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement	AQ
22/09/25	Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM	AQ
02/09/25	Oncopeptides AB - New real-world data confirms efficacy and safety of Pepaxti, presented at IMS Annual Meeting	AQ
16/07/25	Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement	AQ
16/06/25	Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel	AQ
11/06/25	Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders	AQ